Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: walking

Donah Zack Crawford in the Spotlight: Why the ARHP Is for Me

  |  

Donah Zack Crawford, MA, was a research coordinator at the University of Pennsylvania, focused on pre­menstrual syndrome and peri­menopause, when her symptoms first started. “Someone suggested I see a rheumatologist,” she says, and not long after, Philadelphia-based physician Bruce Hoffman, MD, diagnosed her with rheumatoid arthritis. It was the mid-1990s, and treatment options were limited….

Lupus Patient Develops Miller Fisher Variant of Guillain-Barré Syndrome

Sedrick Bradley, MD, & Nirupa J. Patel, MD  |  

Systemic lupus erythematosus (SLE) is a heterogeneous, auto­immune, inflammatory, connective tissue disease affecting multiple organs. Neither central nervous system nor peripheral nervous systems are spared. The neurologic system is involved in a wide range of 10–80% of patients with SLE. Peripheral neuropathy, such as Guillain-Barré syndrome (GBS) and its variants, can occur in neurologic complications…

Down Time at the 2018 ACR/ARHP Annual Meeting: What to See & Do in Chicago

  |  

With the 2018 ACR/ARHP Annual Meeting nearly upon us, the time has come to plan your trip to Chicago. The Annual Meeting is Oct. 19–24 at McCormick Center, which means attendees will see beautiful views of Lake Michigan and the Chicago skyline, highlighting the city’s unique architecture. The weather in October, although unpredictable, is generally…

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD  |  

Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…

Promising Avenues in Myositis: Research Targets Disease Specificity

  |  

AMSTERDAM—Research in myositis treatments is beginning to find its way, with investigators pursuing avenues special to the disease so therapy for patients may no longer involve piggybacking on existing treatments for other illnesses, an expert said at EULAR: the Annual European Congress of Rheumatology. “Finally, in myositis there are targets being investigated that are more…

Art Tours May Have Analgesic Effect for Chronic Pain Patients

Lisa Rapaport  |  

(Reuters Health)—Art museums may have an analgesic effect on chronic pain, a small study suggests. Chronic pain sufferers who took guided tours of art museums felt less discomfort and unpleasantness related to their pain shortly afterward, researchers found. The researchers invited 54 visitors to the Crocker Art Museum in Sacramento, Calif., who reported experiencing chronic…

Coding Corner Question: To Bill or Not to Bill an Eval & Management Visit?

  |  

Scenario 1 History: A 45-year-old male patient with sero-negative rheumatoid arthritis affecting multiple sites, but with no organ or systems involvement, comes for a follow-up visit. The patient reports swelling of the left knee with throbbing left knee pain. He rates the severity of his pain at an 8 on a 10-point scale. The pain…